DETERMINATION OF THE ABSOLUTE BIOAVAILABILITY OF GSK2118436 FOLLOWING A SINGLE ORAL DOSE CO-ADMINISTERED WITH AN INTRAVENOUS RADIOLABELLED MICROTRACER OF GSK2118436 IN SUBJECTS WITH BRAF MUTANT SOLID TUMORS: